For patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma (mUM) assigned to tebentafusp (IMCgp100), circulating tumor DNA (ctDNA) was an improved predictor of survival compared to RECIST 1.1, according to findings presented at the 2021 European Society for Medical Oncology Congress.1
2021
Australian researchers make melanoma treatment breakthrough
Australian researchers have discovered a new weapon in the fight against melanoma.
Study Suggests Which Melanoma Patients May Avoid Sentinel Node Biopsy
Results from a large cohort study indicate that a proportion of stage pT1b-pT2a melanoma patients could potentially avoid entinel lymph node biopsy (SLNB).
Source of DNA mutations in melanoma
The mutations that give rise to melanoma result from a chemical conversion in DNA fueled by sunlight — not just a DNA copying error as previously believed, reports a study by Van Andel Institute scientists published today in Science Advances.